Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
Vitamin D, Magnesium And Calcium In Chronic Obstructive Pulmonary Disease (COPD)
This study will investigate the serum level of vitamin D, magnesium and calcium in patients with chronic obstructive pulmonary disease (COPD) in order to evaluate the impact of vitamin D, magnesium and calcium on lung function in COPD-patients.
Attention is enhancing worldwide on the increasing tendency of insufficient
25-hydroxyvitamin D serum levels. New insights into the role of vitamin D and distribution
of its receptors in the human body have been revealed. Presumably, this entails implications
concerning disease and treatment that go far beyond the well-known field of bone-metabolism.
Vitamin D deficiency is common in patients with chronic obstructive pulmonary disease
(COPD), and reductions in vitamin D serum levels have formerly been perceived as a
consequence rather than a cause of COPD.
Yet, there is a lack of consensus concerning the role of vitamin D on the decreasing lung
function in COPD.
Some trials have revealed a high degree of co-variation between the grade of airway
obstruction, intake of vitamin D and reduction of serum-vitamin D. Other claim that vitamin
D appears to be capable of inhibiting pulmonary inflammatory responses.
Vitamin D interacts with calcium and magnesium and this subtle balance might be highly
relevant in the progression of inflammatory diseases like COPD. Presumably, Mg inhibits
contraction and relaxes smooth muscles in airways due to blocking of calcium-ion-flux across
the cell membrane.
The aim of this study is to investigate the status of vitamin D, magnesium and calcium in
COPD, and to study the relationship and impact of vitamin D, magnesium and calcium in
COPD-patients.
The hypothesis of this study is that COPD-patients with vitamin D-, magnesium- and calcium
supplement have a better lung function and quality of life, than those who have vitamin D-,
magnesium- and calcium deficiency.
;
Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
| Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
| Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
| Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
| Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
| Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
| Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
| Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
| Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
| Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
| Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
| Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
| Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
| Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
| Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
| Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |